Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Previously Treated With Linvoseltamab

Sponsor
Regeneron Pharmaceuticals
Study ID
NCT06631677
Status
Available

Conditions

  • Food Allergy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an expanded access program of dupilumab. The objective of the program is to provide continued dupilumab to adult participants with severe IgE-mediated food allergy who were previously treated with a short course of linvoseltamab and background dupilumab in the parent study R5458-668-ALG-2219 (NCT06369467).

Key Dates

First listed
Oct 8, 2024
Status verified
Jun 2026

Central Contacts

  • Requests for compassionate use must be initiated by a treating physician. Physicians should contact
    844-734-6643
    [email protected]

Related Studies